Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Single versus multiple primary melanomas: Old questions and new answers.
Hwa C, Price LS, Belitskaya-Levy I, Ma MW, Shapiro RL, Berman RS, Kamino H, Darvishian F, Osman I, Stein JA.
Cancer. 2012 Jan 13. doi: 10.1002/cncr.27407. [Epub ahead of print]
Related citations
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26724. [Epub ahead of print]
Behavioral determinants of successful early melanoma detection: Role of self and physician skin examination.
Swetter SM, Pollitt RA, Johnson TM, Brooks DR, Geller AC.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26707. [Epub ahead of print]
Examining the pathways linking lower socioeconomic status and advanced melanoma.
Pollitt RA, Swetter SM, Johnson TM, Patil P, Geller AC.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26706. [Epub ahead of print]
Duke University researchers develop laser-based tool for melanoma.
Printz C.
Cancer. 2011 Oct 1;117(19):4338-9. doi: 10.1002/cncr.26547. No abstract available.
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.
Jensen TO, Schmidt H, Møller HJ, Donskov F, Høyer M, Sjoegren P, Christensen IJ, Steiniche T.
Cancer. 2012 May 1;118(9):2476-85. doi: 10.1002/cncr.26511. Epub 2011 Sep 22.
Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma.
Erman AB, Collar RM, Griffith KA, Lowe L, Sabel MS, Bichakjian CK, Wong SL, McLean SA, Rees RS, Johnson TM, Bradford CR.
Cancer. 2012 Feb 15;118(4):1040-7. doi: 10.1002/cncr.26288. Epub 2011 Jul 19.
Prognostic significance of RUNX3 expression in human melanoma.
Zhang Z, Chen G, Cheng Y, Martinka M, Li G.
Cancer. 2011 Jun 15;117(12):2719-27. doi: 10.1002/cncr.25838. Epub 2010 Dec 23.
A phase 2 trial of dasatinib in advanced melanoma.
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M.
Cancer. 2011 May 15;117(10):2202-8. doi: 10.1002/cncr.25766. Epub 2010 Nov 29.
Overall survival and PD-L1 expression in metastasized malignant melanoma.
Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C.
Cancer. 2011 May 15;117(10):2192-201. doi: 10.1002/cncr.25747. Epub 2010 Nov 29.
Marital status and stage at diagnosis of cutaneous melanoma: results from the Surveillance Epidemiology and End Results (SEER) program, 1973-2006.
McLaughlin JM, Fisher JL, Paskett ED.
Cancer. 2011 May 1;117(9):1984-93. doi: 10.1002/cncr.25726. Epub 2010 Nov 10.
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.
Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, Shapiro R, Berman R, Darvishian F, Hernando E, Pavlick A, Osman I.
Cancer. 2011 Apr 15;117(8):1711-20. doi: 10.1002/cncr.25643. Epub 2010 Nov 8.
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN.
Cancer. 2011 Apr 15;117(8):1704-10. doi: 10.1002/cncr.25659. Epub 2010 Nov 8.
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D; Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma.
Cancer. 2011 Apr 15;117(8):1697-703. doi: 10.1002/cncr.25631. Epub 2010 Nov 8.
Melanoma's deadly march to the brain: by what route, and can it be stopped?
Othus M, Moon J, Margolin K.
Cancer. 2011 Apr 15;117(8):1560-3. doi: 10.1002/cncr.25716. Epub 2010 Nov 10. No abstract available.
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, Brown MP, Ilaria RL Jr, Millward MJ.
Cancer. 2011 Mar 31. doi: 10.1002/cncr.26068. [Epub ahead of print]
A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430.
Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK.
Cancer. 2011 Mar 31. doi: 10.1002/cncr.26111. [Epub ahead of print]
A phase 2 trial of complete resection for stage IV melanoma : Results of Southwest Oncology Group Clinical Trial S9430.
Ollila DW.
Cancer. 2011 Mar 31. doi: 10.1002/cncr.26118. [Epub ahead of print] No abstract available.
Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: A 20-Year Experience.
Kelly P, Zagars GK, Cormier JN, Ross MI, Guadagnolo BA.
Cancer. 2011 Mar 28. doi: 10.1002/cncr.26088. [Epub ahead of print]
Error occurred: cannot get document summary
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on